Asset Details
Do you wish to reserve the book?
Comparative Evaluation of Prolonged Dual Antiplatelet Therapy versus Conventional Regimens on Prognosis in Patients with High Residual Inflammatory Risk: Results from a Prospective Observational Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparative Evaluation of Prolonged Dual Antiplatelet Therapy versus Conventional Regimens on Prognosis in Patients with High Residual Inflammatory Risk: Results from a Prospective Observational Study
Do you wish to request the book?
Comparative Evaluation of Prolonged Dual Antiplatelet Therapy versus Conventional Regimens on Prognosis in Patients with High Residual Inflammatory Risk: Results from a Prospective Observational Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparative Evaluation of Prolonged Dual Antiplatelet Therapy versus Conventional Regimens on Prognosis in Patients with High Residual Inflammatory Risk: Results from a Prospective Observational Study
2026
Overview
High residual inflammatory risk (hs-CRP≥2mg/L) predicts worse prognosis and increased ischemic risk following percutaneous coronary intervention (PCI). The optimal duration of dual antiplatelet therapy (DAPT) and its risk-benefit profile in post-PCI patients with high residual inflammatory risk remain unclear.
Patients undergoing PCI with high residual inflammatory risk at Fuwai Hospital were consecutively enrolled. Patients were stratified into two groups based on DAPT duration: prolonged (>12 months) and conventional (≤12 months) groups. The primary outcome was a composite endpoint of all-cause death, myocardial infarction, definite or probable stent thrombosis, or stroke at 3 years. The key safety outcome was the 3-year rate of Bleeding Academic Research Consortium 2, 3, or 5 bleeding.
Among post-PCI patients with high residual inflammatory risk, 2440 individuals (69.5%) continued DAPT beyond 12 months. After three years of follow-up, prolonged DAPT was associated with a significantly lower risk of the primary outcome (1.5% vs. 4.2%; adjusted hazard ratio [HR]: 0.347, 95% CI: 0.224-0.539). Similar benefits were observed for net adverse clinical events (1.4% vs. 4.1%; adjusted HR: 0.338, 95% CI: 0.216-0.53) and for the composite endpoint of all-cause death or myocardial infarction (0.6% vs. 3.1%; adjusted HR: 0.182, 95% CI: 0.097-0.341). Notably, the key safety endpoint did not differ significantly between the two DAPT durations during follow-up (1.0% vs. 1.2%; adjusted HR: 0.793, 95% CI: 0.401-1.57).
In patients who underwent PCI with high residual inflammatory risk, prolonged DAPT improved clinical outcomes by mitigating ischemic risk without increasing clinically significant bleeding.
Publisher
Dove Press,Dove Medical Press
